AG
NBIX icon

Artal Group’s Neurocrine Biosciences NBIX Stock Holding History

Artal Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250,000
Closed -$21.1M – 130
2017
Q4 		$19.4M Sell
250,000
-150,000
-38% -$10.2M 0.29% 28
2017
Q3 		$24.5M Sell
400,000
-150,000
-27% -$7.91M 0.42% 15
2017
Q2 		$25.3M Buy
550,000
+225,000
+69% +$10.9M 0.44% 19
2017
Q1 		$14.1M Buy
325,000
+175,000
+117% +$7.5M 0.31% 28
2016
Q4 		$5.8M Buy
150,000
+50,000
+50% +$2.26M 0.13% 52
2016
Q3 		$5.06M Buy
100,000
+5,000
+5% +$249K 0.1% 54
2016
Q2 		$4.32M Buy
+95,000
New +$4.37M 0.09% 44

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's NBIX Position: Q1 2018 in Review

Artal Group sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 250,000 shares — an estimated $21.1M sold.

Artal Group first reported a position in NBIX in Q2 2016 and held it in 7 quarters. The position peaked at $25.3M in Q2 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • Artal Group reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • Artal Group sold 250,000 Neurocrine Biosciences shares in Q1 2018, an estimated $21.1M.
  • Artal Group first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 7 quarters.
  • Artal Group's Neurocrine Biosciences position peaked at $25.3M in Q2 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.